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Immunohistochemistrywn to inhibit the replication of human inﬂuenza A virus (IAV) in vitro, their in
vivo expression during IAV infection is not known. Here we investigated mRNA and protein expression of
several β-defensins in the airways of IAV infected mice. Expression of murine β-defensin (MBD)-3 and -4 was
enhanced (3 to 5-fold, pb0.01) in infected lungs, trachea and sinonasal mucosa. MBD-3 and -4 expressions
were correlated with the time course of acute IAV infection suggesting their induction by IAV infection.
Infected mice also showed increased levels of surfactant protein-D especially in the sinonasal mucosa. MBD-3
and -4 were localized to the conducting airway epithelial cells but not the alveolar tissue. We conclude that
IAV infection upregulated the expression of inducible β-defensins in both the upper and lower airways. These
novel ﬁndings suggest that β-defensins might contribute to innate and adaptive immune responses targeted
against IAV infection.
© 2008 Elsevier Inc. All rights reserved.Introduction
Human inﬂuenza A virus (IAV) is a major cause of morbidity and
life-threatening respiratory tract disease worldwide. Although adap-
tive immunity against IAV has been extensively investigated, the
components and interactions among the elements of innate immunity
in IAV infection are less well studied (Wright et al., 2007). The main
site of IAV infection is the respiratory mucosa including sinonasal,
bronchiolar epithelium and the alveolar cells in which uncontrolled
infection can often lead to signiﬁcant lung pathology. After the initial
exposure to IAV, virus infection advances rapidly reaching peak viral
titers in the upper airway within 48 h after infection. This is readily
demonstrated in experimentally infected people (Murphy et al., 1998)
and in laboratory animals such as mice, ferrets, cotton rats and guinea
pigs (Gubareva et al., 1998; Lowen et al., 2006; Ottolini et al., 2005;
Zitzow et al., 2002). Thus, early virus–host interactions and innate
immune defenses are likely to be important in the outcome and
recovery from infection, and are crucial in immunologically naïve
persons who lack speciﬁc adaptive defenses against IAV. Since the
primary concern for IAV outbreaks is antigenic shift that greatly
increases the non-immune population, there is clearly a need to better
understand early innate responses to IAV.gy, University of Mississippi
216, USA. Fax: +1 601 8155377.
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l rights reserved.In addition to protective mechanisms involving anatomic barriers
and the mucociliary clearance apparatus, airway defenses include
epithelial and inﬂammatory cells such as eosinophils, phagocytic
neutrophils and macrophages. These cells express various pattern
recognition receptors including toll-like receptors (TLRs), C-type lectin
receptors, and scavenger receptors that are activated by microbial
pathogens leading to the release of a myriad of defense molecules
including surfactant proteins (SP-D) and antimicrobial peptides (Ganz
2003; Selsted and Quellettee, 2005; Wright 2005). In addition to
directly killing microbes, certain antimicrobial peptides have been
shown to trigger and facilitate the induction of host adaptive immune
responses (Selsted and Quellettee, 2005). For instance, the epithelial
derived β-defensins are chemotactic for various immune cells
including memory T cells, monocytes and immature dendritic cells
via speciﬁc chemokine receptors (Selsted and Quellettee, 2005; Yang
et al., 1999).
β-defensin constitutes one of two major defensin subfamilies and
are differentiated from the α-defensins by structural differences. Both
of these defensins are small (2–6 kDa), cysteine-rich, cationic peptides
that are known for their broad-spectrum antimicrobial activity against
bacteria, fungi and viruses (Selsted and Quellettee, 2005; Lehrer
2004). In mammals, β-defensins are predominantly produced by
barrier epithelial cells whereasα-defensins such as human neutrophil
peptides (HNP1–3) are mainly stored in the azurophil granules of
neutrophils (Selsted and Quellettee, 2005). Among human β-defen-
sins (HBDs), HBD1 is expressed constitutively by keratinocytes
whereas HBD2–4 are induced via activation of transcription factors
Fig. 1. Time course of virus replication in mice inoculated intranasally with (A) A/Hong
Kong/8/68 (H3N2) and (B) A/Puerto Rico/8/34 (H1N1). Data point represents virus titer
(mean±SD) of the log10 pfu/g of tissue from individual animals (3 mice per group). The
lower limit of virus detection was 50 pfu/g tissue.
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crobial infection and proinﬂammatory stimuli such as interleukin-1,
tumor necrosis factor, and lipopolysaccharide. Similarly, murine
β-defensins (MBDs) including MBD-1, -2, -3, and -4 have also been
detected in various mucosal tissues including the airways (Morrison
et al., 1998; Moser et al., 2002; Yasin et al., 2004). These MBDs are
antimicrobial and have been shown to play a role in resistance to
infection (Moser et al., 2002; Morrison et al., 2002; Bals et al., 1999;
Rivas-Santiago et al., 2006).
Recently, several defensins were shown to inhibit IAV replication in
cell cultures and to exert their antiviral effect via a variety of
mechanisms (Hartshorn et al., 2006; Leikina et al., 2005; Salvatore
et al., 2007). For example, HBD-3 and a synthetic primate θ-defensin
have been shown to block viral hemagglutinin induced membrane
fusion (Leikina et al., 2005), whereas HNPs induce impairment of
cellular pathways and increase neutrophil activity (Salvatore et al.,
2007; Tecle et al., 2007). Similarly, these defensins are also inhibitory to
several other enveloped viruses including human immunodeﬁciency
and herpes simplex viruses (Chang et al., 2005; Hazrati et al., 2006;
Quinones-Mateu et al., 2003; Sinha et al., 2003; Yasin et al., 2004; Zhang
et al., 2002). In contrast, there have been few reports on the endogenous
production of defensins during virus infection, and thus, little is known
about the physiological role of defensins in virus infection. Here we
investigated the in vivo mRNA expression and immunolocalization of
defensins in the upper and lower airway of mice infected with two
different IAV strains. In addition, we correlated defensin upregulation
with the time course of IAV infection. We analyzed several MBDs, but
not α-defensins because murine neutrophils express little or no
defensins (Eisenhauer and Lehrer, 1992). Since SP-D have been shown
to interact with defensins in vitro (Hartshorn et al., 2006), we also
investigated SP-D expression in IAV infectedmice in order to determine
if defensins and SP-D are co-stimulated during IAV infection.
Results
Replication of IAV strains in upper and lower airways
We initially determined viral growth in airway tissues over a 7-day
period so thatwe can characterize defensin expression in relation to time
course of infection. To simulate natural infection that primarily targets
the nasal tract, we inoculated mice with small droplets (10 µl) of either
H1N1 or H3N2 inﬂuenza A. Although infected mice showed little
respiratory symptoms, the rate of weight gain in these animals was
lower thanmock-infected mice throughout the duration of experiments.
This reduction in body weight was especially prominent in H1N1
infected mice whose average weight was at 18.5% lower than control
mice. In contrast, H3N2 infected animals showed only a 5.5% decrease in
weight (pb0.05). Infected mice showed very high nasal titers 24 h after
infection and viral levels persisted throughout the 7-day period (Fig. 1).
Viral levels in the paranasal sinus mucosa were about 1.5 log lower
(pb0.01) than nasal titer at 24 h post-infection, but their titers were
more similar at later timepoints. H3N2 virus infected mice showed peak
virus titers early in infection but viral levels declined rapidly beyond day
5 post-infection. Unlike the more mouse-virulent H1N1 virus, H3N2
virus showed lung titers of ~1–4×103 pfu/g, which was 2–3 log lower
compared to nasal, paranasal and trachea mucosa throughout the study
duration (pb0.001). Mice infectedwithH1N1 strain showed signiﬁcantly
higher lung titers (~2×105 pfu/g) on day 1 and 3 post-infection (pb0.01)
andmore persistent viral levels in the trachea but viral titers in nasal and
paranasal sinus mucosa were similar to H3N2 infection (Fig. 1B).
Expression of MBD-1, MBD-2, MBD-3, and MBD-4, SP-D mRNA in
airway tissues
In preliminary analysis, we found that MBD-1 mRNA was readily
detected in mock-infected animals, whereas MBD-3 and MBD-4mRNAs were expressed mainly in infected airway tissues. In contrast,
MBD-2 was detectable only in IAV infected mouse lungs but not in the
upper airway. Similar to MBD-1, SP-D mRNAs were readily detected in
trachea, lungs and sinonasal specimens from both infected and mock-
infected animals. Quantitative RT-PCR analysis were used to deter-
mine the extent of MBD and SP-D expression during early (day 1, 2 and
3) and late (day 6) IAV infection. Fig. 2 shows the levels of MBDs in
infected tissues as expressed as fold change in mRNA expression
relative to the respective mock-infected control airway mucosa. In
sinonasal mucosa, MBD-1, MBD-3 and MBD-4 were modestly
increased throughout the duration of infection except on day 3 post-
infection when MBD-3 had a sharp increase of greater than 5-fold,
which was signiﬁcantly higher than the day 1 value (pb0.01). In lungs,
the expression of all four MBDs were increased by 3 to 5-fold (pb0.01)
on day 2 post-infection but only MBD-3 and MBD-4 were still
modestly elevated by day 6 post-infection. In contrast, trachea showed
little MBD expression during the ﬁrst 2 days of infection but MBD-3
was enhanced by∼4 fold andMBD-4was enhanced by N8 fold on days
3 and 6 post-infection. SP-D expression was also upregulated during
IAV infection especially in the sinonasal mucosa at 2.5 to 5-fold
increase during day 2 and 6 post-infection (Fig. 3). In contrast, there
were a more modest increase in SP-D expression during most
timepoints in the infected lungs although trachea showed 3-fold
increase on day 6 post-infection.
Thus, SP-D, MBD-3 andMBD-4were upregulated in both the upper
and lower airway during IAV infection, whereas MBD-1 and MBD-2
were upregulated only in the lungs. In separate studies, we evaluated
MBD expression using a more mouse-virulent viral strain (H1N1 PR8).
Fig. 3. Expression of surfactant protein-D (SP-D) mRNAs in airway mucosa 3 days post-
infection with A/Hong Kong/8/68 (H3N2). Bars represent mRNA expression normalized
to β-actin and relative to mock-infected mucosa using the 2−ΔΔCT analysis. Error bars
represent the standard error of the mean of 2–3 analysis.
Fig. 2. RT-PCR analysis of murine β-defensins (MBDs) mRNA in sinonasal mucosa (A),
lungs (B) and trachea (C) and at various times post-infection with A/Hong Kong/8/68
(H3N2). MBDs mRNA expression was analyzed by real-time RT-PCR. Bars represent
defensins expression normalized to β-actin and relative to normal mucosa using the
2−ΔΔCT analysis as described inMaterials andmethods. Error bars represent the standard
error of the mean of 2–3 analysis.
Fig. 4. RT-PCR analysis of murine β-defensins (MBDs) mRNA in sinonasal mucosa (A)
and lungs (B) at various time post-infection with A/Puerto Rico/8/34 (H1N1). MBDs
mRNA expression was analyzed by real-time RT-PCR. Bars represent defensins
expression normalized to β-actin and relative to normal mucosa using the 2−ΔΔCT
analysis as described in Materials and Methods. Error bars represent the standard error
of the mean of 2–3 analysis.
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MBD-4 expression in both lungs and the sinonasal mucosa at levels
very similar to infection with H3N2 IAV strain except that there was a
markedly greater increase in both MBD-3 and MBD-4 as early as day
one post-infection in the sinonasal mucosa (Fig. 4).
Histology and immunolocalization of MBDs and SP-D in airway
tissue sections
During the ﬁrst three days of infection, the conducting airway
tissues including trachea, nasal, paranasal, bronchus and bronchioles
showed varying levels of epithelial cell desquamation and inﬂammation(Figs. 5A–C). Infected lungs showed evidence of acute bronchiolitis,
bronchointerstitial pneumonia and alveolitis (Fig. 5A). Between days 5
and 7, most tissues showedmuch less pathology although virus antigen
positive cells were still detectable in sinonasal mucosa. To determine
the level of defensins and SP-D protein expression and localization
Fig. 5. Histological changes in hematoxylin and eosin stained tissues frommice at day 3
post-infection with A/Hong Kong/8/68 (H3N2). Sections shown were lungs (A), trachea
(B) and nasosinus (C). The images shown are representative of multiple sections from
each of three animals at this time point. Scale bar=50 µm.
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speciﬁc antibody preparations. Immunostaining for MBD-1 and MBD-2
were not performed since IAV infection appeared to induce little
enhancement in their expression. As shown in Figs. 6 (A, F, K), IAV viral
proteins were readily detectable in epithelial cells on day 3 after
infection in lungs, trachea and sinonasal mucosa. In mock-infected
animals, only trace levels of MBD-3 and MBD-4 were visible but SP-D
wasmore frequently detectable. In infected animals, MBD-3 andMBD-4
proteins were detectable in the conducting airway mucosa including
the bronchi and bronchioles (Figs. 6C, D), trachea (H, I) and sinonasal
mucosa (M, N) but not in the respiratory bronchioles and the alveoli.
Some epithelial cells were stained for both MBD-3 and MBD-4, but
MBD-4 staining appeared to be more widespread. In contrast, SP-D was
more readily detectable in both the conducting and the respiratory
mucosa including the alveoli (B, G, L). Staining was speciﬁc for MBDs
since tissue sections exposed to serum preparations derived from
preimmune or unrelated immunogens showed no reactivity (E, J, O).
Discussion
This report is the ﬁrst to demonstrate upregulated expression of
epithelial defensins (MBDs) in IAV infected murine upper and lower
airways. Murine models of IAV infection are traditionally establishedby intranasal inoculation with a relatively large volume of virus
(50–150 µl) to anesthetized mice (Bantia et al., 2006). Although this
method yielded more consistent infection and disease severity, it also
lead to an overwhelming infection associated with early and severe
lung involvement, which however, is not characteristic of natural IAV
infection. Studies using tracer dye have shown that intranasal
administration of large ﬂuid volume (N30 µl) in anesthetized mice
will often lead to ﬂooding of the respiratory tract leading to direct
delivery to the lungs (Visweswaraiah et al., 2002). Since our objectives
were to evaluate airwaymucosal defensin expression during sublethal
infection, we thus performed intranasal infection using small
inoculation volume (∼10 µl). As expected our mice showed infection
progression more similar to upper airway infection of humans with
later and lesser lung involvement. Unlike lung virus titers, infected
mice still showed high nasal viral titers by day seven after infection.
Nasal virus titers tend to persist for 7–9 days in animal models during
sublethal infection with many IAV strains. However, the mechanism
for this persistence is not known but could be associated with
reinfection of regenerated airway epithelial cells or to more persistent
infection of long-lived olfactory cells (unpublished data).
In mock-infected mice, MBD-1 was readily detectable in both
upper and lower airways suggesting that its expression is constitutive,
an observation that is consistent with previous reports on MBD-1 and
HBD-1 (Selsted and Quellettee, 2005; Morrison et al., 1998; Moser
et al., 2002; Chen and Fang 2004; Lee et al., 2002). However, we also
noted that infected lungs showed 3-fold increase inMBD-1 expression
two days after IAV infection. Although predominantly constitutive,
HBD-1 is known to be upregulated in certain situations such as in
monocytes exposed to interferon-γ, bacteria or endotoxin (Selsted
and Quellettee, 2005), and in human epithelial cells exposed to poly
(I:C), a Toll-Like-Receptor-3 agonist (Schaefer et al., 2005). In addition,
β-defensin-1 has also been shown to be upregulated in lungs of sheep
infected with parainﬂuenza virus (Gruboret al., 2004). Unlike MBD-1,
mock-infected mice showed little or no MBD-3 andMBD-4 expression
in either the upper or lower respiratory tracts. Importantly, bothMBD-
3 andMBD-4, which are the murine homologs of the inducible human
β-defensin 2 and 3 (Ganz 2003; Bals et al., 1999; Quinones-Mateu
et al., 2003), were signiﬁcantly upregulated in IAV infected airways.
These MBDs were localized predominantly in the conducting
epithelial cells of both upper and lower airways. In the upper airway,
we did not detect consistent immunostaining of either MBD-3 or
MBD-4 in the submucosa glands although HBD-2 is known to be
present in human submucosa gland epithelia (Singh et al., 1998). In
Pseudomonas aeruginosa infected mice, Bals et al. (1999) showed
that MBD-3 transcripts were present in both small and large airway
conducting epithelial. For human airways, inducible β-defensins have
been shown in nasal mucosa derived from chronic sinusitis patients
(Chen and Fang 2004; Lee et al., 2002), and in cultured bronchial
epithelial cells after infection with rhinovirus (Duits et al., 2003). Our
results showed that MBD-1 was mainly constitutive whereas MBD-3
and MBD-4 were induced during acute infection with either H1N1 or
H3N2 viral strains. These characteristics of MBD expression were also
noted in mice infected with other microbes (Bals et al., 1999; Rivas-
Santiago et al., 2006; Zaalouk et al., 2004). Of the two IAV strains used
in this study, the PR8 H1N1 virus was more virulent and produced
greater lung viral titers and more severe lung pathology. Although
MBD-3 and MBD-4 expressions were greater in PR8 H1N1 virus
infected mouse lungs and nasosinus mucosa, the difference was not
statistically signiﬁcant (pN0.05). Unlike the other MBDs, MBD-2
mRNA was detectable only in IAV infected lungs but not in the
upper airway suggesting that the cellular source of MBD-2 might be
associated with the inﬁltrating immune and inﬂammatory cells.
In uninfected lungs, SP-D is known to be widely expressed
(Wright, 2005), and thus it was not unexpected that our mice with
low grade lung infection showed only modest increase in SP-D
expression. In this regard, our ﬁndings were in agreement with a
Fig. 6. Immunohistology of tissues from mice at day 3 post-infection with A/Hong Kong/8/68 (H3N2). Pictures shown are representative of the lungs (A–E), trachea (F–J) and
nasosinus (K–O) from IAV-infected and mock infected (E, J, O) control mice (CTL). Immunostaining were performed using polyclonal antibody preparations against IAV (A, F, K) SP-D
(B, G, L), MBD-3 (C, H, M) and MBD-4 (D, I, N). Tissue sections of lung (E), trachea (J), and sinonasal mucosa (O) exposed to serum preparations derived from preimmune or unrelated
immunogens showed no reactivity. Arrows indicate positive staining (brown). The images shown are representative of multiple sections from each of three animals at this time point.
Scale bar=50 µm.
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2-fold in infected lung as measured by ELISA assay (LeVine et al.,
2001). In contrast, infected mice showed a much higher increase
(N4-fold) in SP-D levels in the sinonasal mucosa that persisted for at
least six days after infection. Since the nasal sinus mucosa were
heavily infected, this suggested that SP-D was induced by IAV
infection. Although SP-D is believed to be protective against IAV
infection, most evidence to date has come from in vitro studies
(Wright, 2005). More recently, IAV infected SP-D knockout (SP-D−/−)
mice were shown to develop more severe infection and inﬂamma-
tory response (LeVine et al., 2001; Li et al., 2002). However, the
tissue expression and cellular localization of SP-D during experi-
mental IAV infection were not previously known. Thus, our dem-
onstration of the upregulation of SP-D in the trachea and sinonasal
mucosa provides evidence that SP-D plays a role in IAV infection of
the upper airway in complement to its previously reported role in
lung infection. Our ﬁnding is relevant to IAV infection in human since
SP-D expression have recently been demonstrated in human
sinonasal epithelia (Kim et al., 2007; Ooi et al., 2007).
In our study, the time course of both defensins and SP-D expression
suggested that these mediators were induced by IAV infection in both
the lower and upper airways. Previously, the extent of humanrhinovirus growth has been shown to correlate with induction of
HBD-2 mRNA and proteins in nasal epithelial cells both in vitro and in
vivo (Proud et al., 2004). In our studies, levels of MBD-3 and MBD-4
increased during acute infection and decreased to near baseline levels
late in infection suggesting that they likely play a role in recovery from
infection. We did not observe a clear correlation between the extent
of defensin upregulation and viral titers in speciﬁc organs. During
acute infection, the release of proinﬂammatory cytokines and
activation of transcription factors are important triggers of defensin
upregulation. However, due to host variables in vivo, the production
of proinﬂammatory cytokines is often not directly proportional to
viral load. Since defensins are part of a ﬁrst-line defense, it is perhaps
not surprising that in our infected mice, defensin upregulation was
not closely dependent on viral load. An alternate explanation for
our not seeing a better correlation between viral loads and defensin
expression is that our experimental approach failed to detect the
correlation. Our data showed a rather large range of mRNA expres-
sion levels that might have resulted from inherent inconsistency in
tissue sampling. For instance, as with most analysis of mRNA ex-
pression in tissues, we isolated total RNA from tissue fragments from
large organs such as lungs, which were not evenly infected in vivo.
Therefore, there likely will be differences in the property of infected
141K.T. Chong et al. / Virology 380 (2008) 136–143tissues from individual animals that were subjected to mRNA
analysis. In contrast, viral assays were more representative of total
lung infection since viral titers were determined in whole lung
homogenates. In future studies, we could improve correlation
analysis by the use of laser-capture microdissection procedure that
can better deﬁne target tissue for mRNA analysis.
Our results show that mucosal defensins and SP-D were
concurrently expressed in IAV infected organs, which conﬁrmed
that they are components of the innate defense repertoire. However,
there were differences in the localization of SP-D and the inducible
β-defensins. For example, SP-D was distributed widely within the
lungs including both the conducting and respiratory epithelia
whereas MBD-3 and MBD-4 were localized predominantly in the
conducting airways including nasal, trachea, bronchi and bronchiole
but not in the respiratory alveoli. Thus, our results suggested that
defensins, due possibly to their highly lytic properties were not
employed in the delicate alveolar tissue. Our mouse ﬁndings might
be relevant to inﬂuenza virus infection in human since HBD-4 was
recently identiﬁed in human lung tissues and importantly, HBD-4
was also shown to be present in bronchial and bronchiolar
epithelium but not in the alveolar cells as evidenced by immuno-
histochemistry analysis (Yanagi et al., 2005). Early defensin induc-
tion allows them to serve as signaling molecules that facilitate the
generation of adaptive immune responses. Although our study was
not designed to analyze the molecular mechanisms of defensin
induction, TLR-mediated events such as the production of proin-
ﬂammatory cytokines are likely to be involved since their activations
are known to induce β-defensins expression in various tissues
(Selsted and Quellettee, 2005). In our infected mice, MBD induction
was more pronounced beyond 2 days after infection, which
suggested that MBDs might be induced by proinﬂammatory
cytokines including tumor necrosis factor, interleukin-1α, inter-
feron-α and γ that are known to be expressed very early during IAV
infection (Ottolini et al., 2005).
In recent years, defensin peptides have attracted increasing
interest as potential wide-spectrum antiviral peptide therapeutic
agents. Accordingly, recombinant and synthetic defensin peptides
have been evaluated in vitro against several viruses (Leikina et al.,
2005; Hazrati et al., 2006; Quinones-Mateu et al., 2003; Sinha et al.,
2003; Yasin et al., 2004; Zhang et al., 2002). Since defensins are often
inactive in the presence of physiological concentration of salt and
serum (Ganz 2003; Selsted and Quellettee, 2005; Dorschner et al.,
2006), their in vivo applications have recently been studied (Brandt
et al., 2007; Elahi et al., 2006). Currently, very little is known about the
endogenous production of defensins during natural viral infection. In
our study, we showed that several β-defensins were upregulated in
both the upper and lower respiratory tracts. Our ﬁndings suggested
that β-defensins might contribute to innate and adaptive immune
responses targeted against IAV infection. In addition, our results
provide a rationale for the development of defensin-based therapy for
IAV using exogenous defensin preparations or by enhancing the
production of de novo defensins in target epithelial surfaces. With
current interest in using exogenous defensins to trigger adaptive
immune responses and activate professional antigen-presenting cells
via Toll-like receptors (Selsted and Quellettee, 2005; Yang et al., 1999;
Schaefer et al., 2005; Claeys et al., 2003; Froy, 2005; Funderburg et al.,
2007; Yang et al., 2000), our ﬁndings might also be important for IAV
vaccine development.
Materials and methods
Animals
Speciﬁc-pathogen and respiratory disease free female C57BL/6
mice, 5–6 weeks old, (Jackson Laboratory, Bar Harbor, Maine) were
used in all experiments. After 5–6 days quarantine, mice were ran-domly distributed into ﬁlter-top polycarbonate cages. Standard rodent
chow and water were provided ad libitum, and all animals were
maintained and handled in accordance with the guidelines set forth
by the Institutional Animal Care and Use Committee at the University
Mississippi Medical Center.
Virus stocks and culture
Inﬂuenza viruses A/Puerto Rico/8/34 (H1N1) and A/Hong Kong/8/
68 (H3N2) were obtained from ATCC and were grown in the allantoic
cavity of 10-day-old embryonated hen eggs and stored as infectious
allantoic ﬂuid as previously described (Lowen et al., 2006; Zitzow
et al., 2002). Virus titers were determined by plaque assay on Madin
Darby canine kidney cells (MDCK) cells in medium overlays contain-
ing1–2 µg/ml TPCK-trypsin as previously reported (Gubareva et al.,
1998). Culture plates were incubated for 72 h at 37 °C and plaques
were counted under a dissecting scope and expressed as pfu/ml of
ﬂuid or pfu/g of tissue.
Infection of mice
For virus infection, groups of 12–15 mice were lightly anesthetized
with isoﬂurane vapor and inoculated intranasally with 106 PFU of
virus at 10-µl per nare in both nostrils. For tissue harvest, group of 3
mice were sacriﬁced at various times post-infection. Sinonasal
compartments were microdissected as previously described (Fanucchi
et al., 1999; Jacob and Chole, 2006). The head of each mouse was
removed from the carcass, the lower jaw and skin were removed, and
the head was split in half along the medial suture. Mucosa lining the
septum, maxilloturbinates, nasoturbinates, and ethmoturbinates were
removed by careful blunt dissection using ﬁne ophthalmic surgical
instruments and a Zeiss stereo zoom microscope. After collection,
nasosinus mucosa, trachea and lung tissue were weighed, homo-
genized in culture media and supernatant were stored at −80 for virus
plaque assays. In separate group of similarly infected mice, trachea,
lung, and sinonasal mucosa were collected on day 1, 2, 3 and 6 days
post-infection and stored immediately in RNAlater (Ambion) at −80 °C
for subsequent isolation of total RNA. Mock-infected animals were
used as normal controls.
RNA extraction, reverse transcription and real-time PCR
Total RNA was extracted from tissue specimens using TRIzol
Reagent as we previously reported (Chong et al., 2006). RNA samples
were resuspended in DEPC-treated water and treated with DNase
(DNA-Free, Ambion) to remove DNA contamination before cDNA
synthesis. Total RNA was reverse transcribed with an iScript cDNA
synthesis kit according to the manufacturer's instructions (Bio-Rad
170-8891). The synthesized cDNA was then ampliﬁed by PCR using
speciﬁc sense and antisense primers for the genes of interest along
with a housekeeping gene, β-actin, as control (see Table 1 for the
primer sequences).
Real-time SYBR-green PCR assays were performed using an iCycler
IQ™ Real-Time PCR detection system (Bio-Rad Laboratories, Hercules,
CA) as we previously described (Chong et al., 2006). Calculation of CT,
standard curve preparation and quantiﬁcation of mRNA in the
samples were performed by the “post run data analysis” software
provided with the iCycler system. Thermal cycling conditions for PCR
reactions consisted of an initial denaturing step (96 °C, 5 min)
followed by 40 cycles of denaturing (94 °C, 30 s), annealing (30 s at
temperatures for speciﬁc primers), and extension (72 °C, 30 s),
followed by ﬁnal elongation for 3 min at 72 °C. Each sample was
loaded in triplicate and run at 40 cycles under the conditions stated
above. To conﬁrm ampliﬁcation of speciﬁc transcripts, agarose gel
electrophoresis was performed initially to conﬁrm that a single
product of expected length was ampliﬁed, and melting curves were
Table 1
Primer sequence, annealing temperature and their predicted product sizes
Gene
name
Primer Sequences Product size
(bp)
Ta (°C)
B actin Sense 5′-TGTGATGGTGGGAATGGGTCAGAA 140 67
Antisense 5′-TGTGGTGCCAGATCTTCTCCATGT.
MBD-1 Sense 5′-CCAGATGGAGCCAGGTGTTG-3′ 98 64
Antisense AGCTGGAGCGGAGACAGAATCC-3′
MBD-2 Sense 5′-AAGTATTGGATACGAAGCAG-3′ 83 61
Antisense 5′-TGGCAGAAGGAGGACAAATG-3′,
MBD-3 Sense 5′-GCATTGGCAACACTCGTCAGA-3′ 85 57
Antisense 5′-CGGGATCTTGGTCTTCTCTA-3′
MBD-4 Sense 5′-GCAGCCTTTACCCAAATTATC-3′ 102 58
Antisense 5′-ACAATTGCCAATCTGTCGAA-3′
SP-D Sense 5′-TGTGATGGTGGGAATGGGTCAGAA-3′ 163 61
Antisense 5′-TGTGGTGCCAGATCTTCTCCATGT-3′
142 K.T. Chong et al. / Virology 380 (2008) 136–143generated following each subsequent PCR run. To determine relative
levels of gene expression, the comparative threshold cycle (ΔΔCT)
method was employed (Livak and Schmittgen, 2001). CT was deﬁned
as the cycle number at which reporter ﬂuorescence reached 10 times
the standard deviation of the baseline ﬂuorescence. For each sample,
the mean CT value obtained for β-actinwas subtracted from the mean
CT value for the gene of interest to derive a ΔCT value. The ΔCT of test
samples was then subtracted from ΔCT of the control sample to
generate a ΔΔCT. The mean of these ΔΔCT measurements was then
used to calculate target gene expression normalized to β-actin and
relative to the control as: relative expression=2−ΔΔCT.
Histology and immunohistochemistry
Tissue specimens were ﬁxed in buffered formalin and processed
for routine histological analysis. Tissue sectionswere subjected to heat
mediated antigen retrieval steps in 0.01 M sodium citrate buffer (pH
6.0) and then pretreated to reduce non-speciﬁc staining according to
standard protocols. Immunostaining was performed using commer-
cial polyclonal primary antibody preparations against puriﬁed
inﬂuenza virions (Virostat Inc. Portland, ME), MBD-3, MBD-4 (Santa
Cruz Biotechnology Inc. Santa Cruz, CA) and SP-D (Millipore Corp.
Billerica, MA). After incubation with primary antibody products,
sections were incubated with the appropriate secondary antibody
preparations (Jackson ImmunoResearch, West Grove, PA) and then
stained using Vectastain ABC Kit for streptavidin-HRP and diamino-
benzidine (DAB) chromogen substrate detection (Vector Laboratories,
Burlingame, CA); sectionswere then counterstainedwith hematoxylin
solution. Preimmune and irrelevant antibody preparations were used
as negative staining controls.
Statistical analysis
Viral titers were expressed as means±standard errors of the mean
of 3 mice per time point. For PCR analysis, mRNA expression was
determined from pooled tissues from 2–3 mice and shown as means
±standard errors of the mean of duplicate experiments. Differences in
viral titers or mRNA fold change between groups as speciﬁed in the
Results section were analyzed by the Student t test. A value of pb0.05
was considered the minimal level of signiﬁcance.
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